Results 1 to 10 of about 2,234 (172)

Comparative efficacy of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists with or without dexamethasone for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy (HEC): a network meta-analysis [PDF]

PeerJ
Objective This network meta-analysis evaluated the efficacy of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, with or without Dexamethasone (D), for preventing chemotherapy-induced nausea and vomiting (CINV) in patients undergoing highly emetogenic ...
Hongxia Xu, Jiankun Xing, Shaohui Yang, Lingyan Rong, Lingyan Liu, Xiaotao Chen   +5 more
doaj   +3 more sources

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5-HT₃ Receptor Antagonists: 2026 Update. [PDF]

Clin Pharmacol Ther
5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Moore C, Bourque MS, Halman A, Agúndez JAG, Prows CA, Hikino K, Schwab M, Oxencis CJ, Chauhan D, Diekstra MHM, Long SE, Bell GC, Gaedigk A, Whirl-Carrillo M, Klein TE, Caudle KE, Conyers R.   +16 more
europepmc   +2 more sources

Comparative Cost-Utility and Clinical Efficacy of 5-HT3 Receptor Antagonists in Sufentanil-Based PCIA: A Propensity Score-Matched Analysis [PDF]

Pain and Therapy
Introduction Postoperative pain management using sufentanil-based patient-controlled intravenous analgesia (PCIA) is often compromised by opioid-induced nausea and vomiting.
Youmei Wu, Yingchao Ye, Han Gong, Fangfang Xia   +3 more
doaj   +2 more sources

Prediction of Moderate to Severe Delayed Chemotherapy-Induced Nausea Using a Novel Algorithm Incorporating Individual Patient Factors. [PDF]

Cancer Med
ABSTRACT Purpose Chemotherapy‐induced vomiting and nausea (CINV) is difficult to accurately predict, especially in the delayed phase and can negatively affect a patient's' quality of life as well as reduce their motivation to continue lifesaving therapy.
Maity AP, Kjelstrom SD, Fleck KJ, Zeger EL, Ali ZA, Ghaneie A, Shevade AL, Gilman PB, Savior DC, Wallon UM.   +9 more
europepmc   +2 more sources

A Phase 1 Oral Mass Balance and Combined Intravenous [¹⁴C] Microtracer Study to Characterize the Absorption, Metabolism, Excretion, and Pharmacokinetics of Antitumor Drug E7386 in Humans. [PDF]

J Clin Pharmacol
Abstract E7386, an orally active protein‐protein interaction inhibitor, is reported to impair the interaction between transcriptional co‐activator CREB‐binding protein and β‐catenin. A competent study design exploring the concomitant dosing routes, sensitive intravenous (IV; [14C]) microtracer technology, and oral [14C] radiolabeled dosing was ...
Pathak SM, Hayata N, Ueno T, Aluri J, Wu J, Brooks AS, Laing CM, Dutta L, Yasuda S.   +8 more
europepmc   +2 more sources

Netupitant/Palonosetron [PDF]

Hospital Pharmacy, 2015
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Dennis J, Cada, James, Leonard, Danial E, Baker   +2 more
openaire   +3 more sources

Evaluation of the ability of continuous palonosetron infusion, using a patient-controlled analgesia device, to reduce postoperative nausea and vomiting [PDF]

Korean Journal of Anesthesiology, 2014
BackgroundThe efficacy of palonosetron in preventing postoperative nausea and vomiting (PONV), as well as chemotherapy-induced nausea and vomiting, has already been demonstrated in multiple clinical studies.
Ji Won Kang, Soo Kyoung Park
doaj   +1 more source

Analgesic effects of palonosetron in the intravenous propofol injection [PDF]

Korean Journal of Anesthesiology, 2014
BackgroundPropofol is a good induction agent, but it has the disadvantage of causing pain on intravenous injection. The incidence of propofol-induced pain is approximately 70%.
Han-Bom Ryu, Su-Jin Kim
doaj   +1 more source

The effect of palonosetron on rocuronium-induced withdrawal movement

Brazilian Journal of Anesthesiology, 2017
Background: Rocuronium causes pain and withdrawal movement during induction of anesthesia. In this study, palonosetron was investigated to have analgesic effect on the reduction of rocuronium-induced withdrawal movement.
Ki-Bum Park, Younghoon Jeon, Junggu Yi, Ji-hyun Kim, Seung-Yeon Chung, Kyung-Hwa Kwak   +5 more
doaj   +3 more sources

The comparative study to evaluate the effect of palonosetron monotherapy versus palonosetron with dexamethasone combination therapy for prevention of postoperative nausea and vomiting [PDF]

Korean Journal of Anesthesiology, 2012
Background5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are effective and safe on postoperative nausea and vomiting (PONV). Palonosetron, the newest 5-HT3 antagonist, has potent antiemetic property.
Jung Woo Park, Jin Woo Jun, Yun Hee Lim, Sang Seok Lee, Byung Hoon Yoo, Kye-Min Kim, Jun Heum Yon, Ki Hyuk Hong   +7 more
doaj   +1 more source